Neuraltus Pharmaceuticals, Inc. is a **privately-held** biopharmaceutical company founded in **2004** and headquartered in the **United States**. Focused on **Biotechnology, Health Care,** and **Pharmaceutical** industries, the company is committed to developing and commercializing innovative therapeutics for addressing critical unmet needs in the treatment of neurodegenerative diseases. Their approach involves collaborating with global ALS specialists and seeking input from patient advocacy organizations to inform the clinical development path and better understand the needs of those affected by the disease. The company's latest investment of **$14.94M** came from a **Venture Round** on **24 May 2016**, with investment partners including **Latterell Venture Partners** and **VantagePoint Capital Partners**. Neuraltus Pharmaceuticals' dedication to addressing unmet medical needs and their strategic collaborations position them as a promising venture for potential investors seeking opportunities in the biopharmaceutical sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $14.94M | 2 |
|
24 May 2016 |
| Venture Round | $1.50M | 2 |
|
01 Apr 2012 |
| Series B | $9.60M | 3 |
|
31 Jan 2012 |
| Series A | $11.13M | - | 15 Dec 2011 | |
| Series A | $17.00M | 3 |
|
26 Mar 2009 |
No recent news or press coverage available for Neuraltus Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
